La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Apellis Pharmaceuticals Gestion

Gestion contrôle des critères 2/4

Le PDG Apellis Pharmaceuticals' est Cedric Francois, nommé en Sep2009, a un mandat de 15.08 ans. La rémunération annuelle totale est $ 10.37M, composée du salaire de 7.1% et des bonus 92.9%, y compris les actions et options de la société. détient directement 1.51% des actions de la société, d'une valeur de € 47.73M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 5.7 ans et 9.3 ans.

Informations clés

Cedric Francois

Directeur général

US$10.4m

Rémunération totale

Pourcentage du salaire du PDG	7.1%
Durée du mandat du directeur général	15.1yrs
Propriété du PDG	1.5%
Durée moyenne d'occupation des postes de direction	5.7yrs
Durée moyenne du mandat des membres du conseil d'administration	9.3yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Cedric Francois a-t-elle évolué par rapport aux bénéfices de Apellis Pharmaceuticals?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2024	n/a	n/a	-US$333m
Mar 31 2024	n/a	n/a	-US$417m
Dec 31 2023	US$10m	US$735k	-US$529m
Sep 30 2023	n/a	n/a	-US$606m
Jun 30 2023	n/a	n/a	-US$657m
Mar 31 2023	n/a	n/a	-US$691m
Dec 31 2022	US$9m	US$681k	-US$652m
Sep 30 2022	n/a	n/a	-US$634m
Jun 30 2022	n/a	n/a	-US$638m
Mar 31 2022	n/a	n/a	-US$702m
Dec 31 2021	US$9m	US$647k	-US$746m
Sep 30 2021	n/a	n/a	-US$520m
Jun 30 2021	n/a	n/a	-US$460m
Mar 31 2021	n/a	n/a	-US$360m
Dec 31 2020	US$9m	US$619k	-US$345m
Sep 30 2020	n/a	n/a	-US$536m
Jun 30 2020	n/a	n/a	-US$470m
Mar 31 2020	n/a	n/a	-US$423m
Dec 31 2019	US$4m	US$560k	-US$305m
Sep 30 2019	n/a	n/a	-US$228m
Jun 30 2019	n/a	n/a	-US$194m
Mar 31 2019	n/a	n/a	-US$156m
Dec 31 2018	US$4m	US$550k	-US$128m
Sep 30 2018	n/a	n/a	-US$109m
Jun 30 2018	n/a	n/a	-US$85m
Mar 31 2018	n/a	n/a	-US$64m
Dec 31 2017	US$2m	US$400k	-US$51m

Rémunération vs marché: La rémunération totale de Cedric ($USD 10.37M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché German ($USD 2.49M ).

Rémunération et revenus: La rémunération de Cedric a augmenté alors que l'entreprise n'est pas rentable.

PDG

Cedric Francois (52 yo)

15.1yrs

Titularisation

US$10,373,049

Compensation

Dr. Cedric Francois, M.D., Ph.D. serves as Principal of Vista Therapeutics, Inc. Dr. Francois co-founded Apellis Pharmaceuticals, Inc. in 2009 and has been its Chief Executive Officer, President and Direct...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Cedric Francois	Co-Founder	15.1yrs	US$10.37m	1.51% € 47.1m
Alec Machiels	Co-Founder & Director	15.8yrs	US$495.96k	0.64% € 19.9m
Timothy Sullivan	CFO & Treasurer	7yrs	US$3.74m	0.084% € 2.6m
Adam Townsend	Chief Operating Officer	less than a year	US$3.71m	0.023% € 726.0k
David Watson	General Counsel	10.8yrs	US$4.89m	0.094% € 2.9m
Caroline Baumal	Chief Medical Officer	1.8yrs	US$4.43m	0.0052% € 161.2k
Pascal Deschatelets	Co-Founder & Chief Scientific Officer	15.1yrs	US$3.08m	0.91% € 28.6m
James Chopas	VP, Corporate Controller & Chief Accounting Officer	3.2yrs	pas de données	0.010% € 311.4k
Meredith Kaya	Senior Vice President	no data	pas de données	pas de données
Karen Lewis	Chief People Officer	4.4yrs	pas de données	0.00073% € 22.8k
Peter Hillmen	Head of Hematology Engagement & Member of PNH Scientific Advisory Board	2.4yrs	pas de données	pas de données
Victoria Brown	Senior Vice President	5.7yrs	pas de données	0.0031% € 96.7k

5.7yrs

Durée moyenne de l'emploi

51.5yo

Âge moyen

Gestion expérimentée: L'équipe de direction de 1JK est chevronnée et expérimentée (ancienneté moyenne 5.5 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Cedric Francois	Co-Founder	15.1yrs	US$10.37m	1.51% € 47.1m
Alec Machiels	Co-Founder & Director	15.1yrs	US$495.96k	0.64% € 19.9m
Peter Hillmen	Head of Hematology Engagement & Member of PNH Scientific Advisory Board	9.3yrs	pas de données	pas de données
Lokchung L. Chan	Independent Chairman of the Board	11.3yrs	US$504.08k	0.00056% € 17.5k
Stephanie O'Brien	Independent Director	11.3yrs	US$488.46k	0.00056% € 17.5k
Gabriel Coscas	Member of AMD Scientific Advisory Board	9.3yrs	pas de données	pas de données
Robert Brodsky	Member of PNH Scientific Advisory Board	9.3yrs	pas de données	pas de données
Michael Yeadon	Member of Pulmonology Scientific Advisory Board	9.3yrs	pas de données	pas de données
Paul Fonteyne	Independent Director	4.5yrs	US$489.08k	0.0047% € 145.8k
A. Dunlop	Independent Director	14.6yrs	US$480.96k	0.12% € 3.7m
Marsha Wills-Karp	Member of Pulmonology Scientific Advisory Board	no data	pas de données	pas de données
Carl Atkinson	Member of Pulmonology Scientific Advisory Board	9.3yrs	pas de données	pas de données

9.3yrs

Durée moyenne de l'emploi

57.5yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de 1JK sont considérés comme expérimentés (ancienneté moyenne 9.1 ans).

Apellis Pharmaceuticals Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

Apellis Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024

Chief Technical Operations Officer recently sold €590k worth of stock

Apellis Pharmaceuticals, Inc. Announces Appointment of Philip Ferrone, M.D as Chief Medical Retina Advisor, Effective March 18, 2024

Apellis Pharmaceuticals, Inc. Appoints Adam Townsend as Chief Operating Officer

Co-Founder recently sold €482k worth of stock

Insufficient new directors

Recent updates

Forecast breakeven date pushed back to 2026

Sobi and Apellis Announce Positive Topline Results from Phase 3 Valiant Study of Pegcetacoplan in C3G and Primary IC-MPGN

Forecast to breakeven in 2025

Second quarter 2024 earnings released: US$0.30 loss per share (vs US$1.02 loss in 2Q 2023)

Apellis Pharmaceuticals, Inc. Announces Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress

First quarter 2024 earnings released: US$0.54 loss per share (vs US$1.56 loss in 1Q 2023)

Apellis Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024

Apellis Announces Pegcetacoplan MAA Review Reset to Initial Assessment by European Medicines Agency

Chief Technical Operations Officer recently sold €590k worth of stock

Apellis Pharmaceuticals, Inc. Announces Appointment of Philip Ferrone, M.D as Chief Medical Retina Advisor, Effective March 18, 2024

Full year 2023 earnings released: US$4.45 loss per share (vs US$6.15 loss in FY 2022)

Apellis Pharmaceuticals, Inc. Announces Negative CHMP Opinion for Pegcetacoplan for Ga in the European Union and Plans to Seek Re-Examination of Application

Apellis Pharmaceuticals, Inc. Appoints Adam Townsend as Chief Operating Officer

Co-Founder recently sold €482k worth of stock

Apellis Pharmaceuticals, Inc. Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union

Apellis Pharmaceuticals, Inc. and Sobi Presents Post Hoc Data that Reinforce the Long-Term Efficacy and Safety of EMPAVELI

Insufficient new directors

Apellis Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

Sobi and Apellis Pharmaceuticals, Inc. Announce Positive Results from Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G

Apellis Pharmaceuticals, Inc. Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device to Streamline Self-Administration

Apellis Pharmaceuticals, Inc. Receives Permanent J-Code (J2781) for SYFOVRE® (Pegcetacoplan Injection), Effective October 1, 2023

Levi & Korsinsky, LLP Notifies Investors in Apellis Pharmaceuticals, Inc. of Class Action Securities Lawsuit

Apellis Pharmaceuticals, Inc. Announces Corporate Restructuring to Drive Growth of SYFOVRE and EMPAVELI

Apellis Pharmaceuticals, Inc. Provides Updates on Injection Kits and Rare Safety Events with SYFOVRE (Pegcetacoplan Injection)

Kessler Topaz Meltzer & Check, LLP and Bernstein Litowitz Berger & Grossmann LLP Files Securities Class Action Lawsuit Against Apellis Pharmaceuticals, Inc

No longer forecast to breakeven

Second quarter 2023 earnings released: US$1.02 loss per share (vs US$1.46 loss in 2Q 2022)

Apellis Pharmaceuticals, Inc. Provides Update on Review of Rare Safety Events with SYFOVRE® for Geographic Atrophy

Insufficient new directors

FDA Approves Syfovre (Pegcetacoplan Injection) as the First and Only Treatment for Geographic Atrophy (GA)

Apellis Appoints Retina Specialist Dr. Caroline Baumal as Chief Medical Officer

Forecast to breakeven in 2025

Apellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date of February 26, 2023 for Pegcetacoplan for Geographic Atrophy (GA)

Insufficient new directors

Apellis Pharmaceuticals, Inc. Announces Plans to Submit 24-Month Phase 3 Data to the FDA for Pegcetacoplan NDA for Geographic Atrophy

Apellis Pharmaceuticals, Inc. Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacoplan Led to Preservation of Function in High-Risk Areas of the Retina in Patients with Geographic Atrophy (GA) at AAO Annual Meeting

Apellis Pharmaceuticals, Inc. Announces 24-Month Results Showing Increased Effects Over Time with Pegcetacoplan in Phase 3 DERBY and OAKS Studies in Geographic Atrophy

Apellis Pharmaceuticals, Inc. Announces FDA Acceptance and Priority Review of the New Drug Application for Pegcetacoplan for the Treatment of Geographic Atrophy

Apellis Pharmaceuticals, Inc. Announces Five Oral Presentations in Geographic Atrophy Highlighted at the ASRS Annual Scientific Meeting

Insider recently sold €116k worth of stock

Apellis Pharmaceuticals, Inc. and Sobi(R) Report New Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI (pegcetacoplan) for PNH at EHA 2022 Congress

Apellis Pharmaceuticals, Inc. and Sobi Announces First Patient Dosed in Phase 3 VALIANT Study of Pegcetacoplan for IC-MPGN and C3G, Rare Kidney Diseases with High Unmet Medical Need

Apellis Announces Submission of New Drug Application to the FDA for Pegcetacoplan for Geographic Atrophy

No longer forecast to breakeven

Apellis Pharmaceuticals, Inc. Announces Appointment of Peter Hillmen as Head of Hematology Engagement, Effective May 23, 2022

Apellis Pharmaceuticals, Inc. Announces Detailed 18-Month Results from Phase 3 DERBY and OAKS Studies of Pegcetacoplan for Geographic Atrophy at ARVO Annual Meeting

Insufficient new directors

Apellis Pharmaceuticals, Inc., Annual General Meeting, Jun 01, 2022

No longer forecast to breakeven

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

General Counsel recently sold €51k worth of stock

Forecast to breakeven in 2024

Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (Publ) Announce EU Approval of Aspaveli® (Pegcetacoplan) for Treatment of PNH

Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (publ) Report Empaveli™ Demonstrated Sustained Normalization of Clinical Measures in a Broad PNH Patient Population

Apellis Announces Results from Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA) and Plans to Submit NDA to FDA in the First Half of 2022

Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (Publ) Report Positive Top-Line Results from the Phase 3 Prince Study of EMPAVELI™ (pegcetacoplan) in Treatment-naïve Patients with PNH

Apellis Announces U.S. Food and Drug Administration (Fda) Approval of Empaveli™ (Pegcetacoplan) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)

ApApellis Pharmaceuticals, Inc. to Present Long-Term Pegcetacoplan Data in PNH at the European Hematology Association Virtual Congress

The NEJM Publishes Phase 3 PEGASUS Study Results Comparing Pegcetacoplan to Eculizumab for PNH

Apellis Pharmaceuticals, Inc. Provides Update on APL-9 for Severe COVID-19

New 90-day high: €46.60

Apellis Pharmaceuticals, Inc. Enters into A Commercial Supply Agreement with Bachem Americas, Inc

New 90-day high: €45.40

Swedish Orphan Biovitrum AB and Apellis Pharmaceuticals Inc. Reports Positive Top-Line Results At 48 Weeks from the Phase 3 Pegasus Study of Pegcetacoplan in PNH

New 90-day high: €41.40

Sobi and Apellis Announce First Patient Dosed in Potentially Registrational ALS Study of Pegcetacoplan

Apellis Pharmaceuticals Announces FDA Acceptance and Priority Review of the New Drug Application for Pegcetacoplan for the Treatment of PNH

New 90-day high: €31.20

Apellis, Enters Strategic Collaboration with Sobi to Develop and Commercialize Pegcetacoplan in Hematologic Indications Outside the US